Predictors of elevated transaminase levels in patients with central obesity V. Papastergiou, G. Ntetskas, L. Skorda, F. Lambrianou, K. Roufas, E. Asonitis,

Slides:



Advertisements
Similar presentations
Maenne Okunola Pharm D. Candidate: University of Georgia June 2012 Preceptor: Dr. Ali Rahimi.
Advertisements

Group D Florendo-Gaspar.  Tests based on detoxification and excretory functions  Tests that measure biosynthetic function  Coagulation factors  Other.
L.A. Lesmana Department of Medicine, University of Indonesia, Jakarta.
COLONOSCOPIC FINDINGS IN PATIENTS WITH IRON DEFICIENCY ANEMIA AND NEGATIVE GASTROSCOPY I. Familas, G. Ntetskas, I. Strigklogianis, V. Papastergiou, E.
DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.
Metabolic Syndrome in Non-Diabetics Vilanova Fillat, M.B. Falguera Vilamajó, M. Garriga Badia, A. Miró Vallvé, N. Cebrian Aiguadé, C. Escardó Font, C Bacompte.
ENERGY BALANCE.  BMR is predicted by lean body mass (i.e. total body mass - fat mass), and varies with gender and age.  Extra metabolic energy is consumed.
High-density lipoprotein subclasses in subjects with impaired fasting glucose Filippatos TD 1, Barkas F 1, Klouras E 1, Liontos A 1, Rizos EC 1, Gazi I.
ENDOSCOPIC FINDINGS IN PATIENT PRESENTED WITH HEMATOCHEZIA I. Familas, G. Ntetskas, I. Striglogianis, V. Papastergiou, E. Anastasiou, M. Stampori, E. Asonitis,
NONALCOHOLIC FATTY LIVER DISEASE
Liver Function Tests (LFTs)
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD Featured Article: Jessica Bazick,
S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.
Ontario College of Family Physicians 51 st Annual Scientific Assembly Barry Lumb Fatty Liver Disease.
 Fatty liver disease can range from fatty liver alone (steatosis) to fatty liver associated with inflammation (steatohepatitis). This condition can occur.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Deranged LFTs Pathways A H Mohsen Dr A H Mohsen MD (KCL), MRCP, DTM&H Consultant Gastroenterologist.
F ATTY L IVER Shahin Merat, M.D. Associate Professor of Medicine Digestive Disease Research Center, Tehran University of Medical Sciences, 8 th International.
Fatty Liver and Pregnancy Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1.
Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.
Impact of weight management in chronic HCV Egyptian patients on liver fibrosis. By: Dr. Osama A. Fekry Lecturer of CN at the AUC Head of clinical Nutrition.
Epidemiology of the Metabolic Syndrome in the USA Incidence ? Prevalence Distribution Control ? Incidence ? Prevalence Distribution Control ? Epidemiology.
THE PRESENCE OF HEPATIC STEATOSIS WHEN NO OTHER CAUSES FOR SECONDARY HEPATIC FAT ACCUMULATION NAFLD MAY PROGRESS TO CIRRHOSIS AND IS LIKELY AN IMPORTANT.
Emily O’Brien, Emil Fosbol, Andrew Peng, Karen Alexander, Matthew Roe, Eric Peterson The Obesity Paradox: The Importance for Long-term Outcomes in Non-ST-Elevation.
METABOLIC Syndrome: a Global Perspective
Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.
SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.
Anthropometrics in Obesity Robert Kushner, MD Northwestern University Feinberg School of Medicine.
HEPATITIS C VIRUS REINFECTION IN PEOPLE WHO INJECT DRUG (PWID) PREVIOUSLY SUCCESFULY TREATED G. Ntetskas, V. Papastergiou, L. Skorda, A. Katsili, E. Anastasiou,
Non-alcoholic Fatty Liver Disease
Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.
Diabetes National Diabetes Control Programme
The Use of Mortality Data to Improve Risk Assessment CTHOLUA Seminar February, 2011 Robert Stout, Ph.D., President and Director Clinical Reference Laboratory.
High level of low density lipoprotein cholesterol in adult children of patients with premature coronary heart disease: relation to own and parental characteristics.
Contemporary Management of Cardiometabolic Risk. A continuing epidemic: 2 of 3 US adults are overweight or obese National Health and Nutrition Examination.
Dr. I. Selvaraj Indian Railways Medical Service B.Sc., M.B.B.S., M.D.,D.P.H., D.I.H., PGCHFW ( NIHFW,New Delhi)., Life member of Indian Association of.
Mrs. Watcharasa Pitug ID The Association between Waist-to-Hight ratio, waist circumference,and Body Mass Index as Risk Factors for Chronic.
Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C
Metabolic Syndrome Darwin Deen, MD, MS Albert Einstein College of Medicine Gina Lopez, MSII Sophie Davis School of Biomedical Education.
Chapter 14 Patterns in Health and Disease: Epidemiology and Physiology EXERCISE PHYSIOLOGY Theory and Application to Fitness and Performance, 6th edition.
Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.
Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease : The St Francis Heart Study Randomized Clinical Trial Temitope Foster,
Jun Yu,1,2 Joseph Jao-Yiu Sung,1,2 Henry Lik-Yuen Chan1,2
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.
PREVALENCE AND RISK FACTORS FOR NON- ALCOHOLIC FATTY LIVER DISEASE AMONG AN URBAN AGING ADULT SRI LANKAN POPULATION– RAGAMA HEALTH STUDY 7-YEAR FOLLOW.
Kris V. Kowdley, Patricia Belt, Laura A. Wilson, Matthew M. Yeh, Brent A. Neuschwander-Tetri, Naga Chalasani, Arun J. Sanyal, and James E. Nelson ; for.
Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients Giovanni Targher, Lorenzo Bertolini, Felice Poli,
Alcoholic liver disease and non-alcoholic fatty liver disease
Risk of Severe Fibrosis is Associated with Time from Menopause
results of the METAFIB study
The magnitude of hepatic enzyme rise and it’s correlation with the severity of Dengue Hemorrhagic Fever Muhammad Abdur Rahim 1, Khwaja Nazim Uddin 2, AKM.
OBESITY.
Independent variables (baseline) Loge (HOMA-IR) b P
Guidelines for the diagnosis and management of Nonalcoholic Fatty Liver Disease (NAFLD): Update in 2012 Sameh M Fakhry MD, Msc, PhD Consultant of Gastroenterology,
ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
Underwriting Screening Liver Test Abnormalities:
Norbert Stefan, Fritz Schick, Hans-Ulrich Häring  Cell Metabolism 
Screening and Monitoring
Doyle M. Cummings, Pharm.D.,FCP, FCCP
Figure 1 Proposed algorithm for the management
Journal-Club Natalie Geider
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Maya Gambarin–Gelwan, Sanjiv V. Kinkhabwala, Thomas D
Impact of metabolic risk factors on HCC
Selonsertib in NASH: phase 2
Response to abnormal liver blood tests.
Fig. 3. Differences in the prevalence of albuminuria after comorbidity stratification. (A) Obesity defined by a body mass index ≥25 kg/m2, (B) central.
Presentation transcript:

Predictors of elevated transaminase levels in patients with central obesity V. Papastergiou, G. Ntetskas, L. Skorda, F. Lambrianou, K. Roufas, E. Asonitis, M. Stampori, C. Psellas, I. Karagiorgi, S. Karatapanis First Department of Internal Medicine, General Hospital of Rhodes,

Nonalcoholic fatty liver disease Common indolently progressive liver disease Range from simple steatosis, through the more severe nonalcoholic steatohepatitis (NASH), to advanced fibrosis/cirrhosis Strongly related to insulin resistance and obesity hepatic component of the metabolic syndrome Angulo, NEJM, 2002 Marchesini, Hepatology, 2003

ALT Elevated activities may be associated with liver disease Strongly related to obesity, diabetes, dyslipidemia Prevalence elevated ALT: 7.9% in general population, 20% in diabetics, >80% in candidates for bariatric surgery Elevation may act as a surrogate of NAFLD presence Trombetta, APT, 2005 Angulo, NEJM, 2002

ALT More related to fat accumulation than AST Activity in the hepatocytes is 7000 fold greater than in the serum Marker 0f NAFLD in many epidemiological studies Westerbacka, Diabetologia, 2004 Clark, Gastroenterology, 2003

Elevated ALT Predictive of the presence of NAFLD, if two basic criteria are met: Exclusion of alternative liver disease (eg; viral hepatitis, ALD, haemochromatosis) Presence of features of the metabolic syndrome Clark, Am J Gastr, 2003

Abdominal obesity “ upper body” obesity M>F Adiposity in subcutaneous and intra-abdominal compartments (visceral fat) Predictor of adverse metabolic/cardiovascular outcomes irrespective to BMI (reflects general obesity) Waist Circumference (WC) convenient measure of abdominal obesity Included as a criterion for the definition of metabolic syndrome (IDF 2009 revision) ≥ 94 cm in men ≥80 cm in women

Magnitude of elevated liver enzymes (LIFTs) in subjects with increased WC remains limited Few data in the Greek population AIM To estimate the prevalence of elevated liver enzymes among subjects with increased WC and to determine the associated factors

Methods Study population Consecutive adults undergoing abdominal ultrasonography WC: ≥ 94 cm in men, ≥80 cm in women

Exclusion criteria Alcohol consumption (>20 gr/day in women, >30 gr/day in men) Seropositivity for viral hepatitis (HBsAg, anti- HCV) Clinical/biochemical evidence of other liver disease (autoimmune, PBC, haemochromatosis, Wilson)

Recorded variables Demographics WC BMI ALT Alkaline phosphatase Serum triglycerides γ-GT Ultrasonographic features consistent with fatty liver (diffuse increase in liver echogenicity as compared with that of the kidneys) HOMA-IR (IR was considered with HOMA > or =2)

Data analysis Patients were divided in 2 groups: -increased ALT (M: >30 IU/mL, F: >20 IU/mL) -normal ALT Multivariate regression was carried out to identify predictors associated with increased ALT.

Results 211 subjects included 139 (65.9%) males Mean age: 43.8±9.2 years Mean WC: 95.2± (0.9%) normal (BMI<25 Kg/m 2 ) 97 (46%) overweight (BMI 25 to 29.9 Kg/m 2 ) 112 (53.1%) obese (BMI >30 Kg/m 2 )

Abnormal LFTs ALT: 39 (18.5%) AST: 15 (7%) G-GT: 20 (9.5%) ALP: 7 (3.5%) 50 (23.7%) patients had an increase in at least 1 liver enzyme

U/S – “bright” liver 41 (19.4%) patients

Distribution of increased ALT according to Gender and BMI category

Univariate analysis Normal ALT (n=172) Elevated ALT (n=39) P-value Age; years (mean) Male Gender (n,%) 106 (61.6)33 (84.6)< HOMA>2 (n, %)22 (12.8%)18 (46.2%)< BMI; Kg/m 2 (mean) Triglycerides ; mg/dL (mean) < U/S -bright liver (n, %) 20 (11.6)21 (53.8)< g-GT; IU/mL (mean) ALP; IU/mL (mean)

Multivariate analysis VariableOdds ratio (95% CI) Male gender1.8 ( ) HOMA-IR>21.9 ( ) Triglyceride levels2.3 ( )

Conclusions The prevalence of abnormal LFTs in a Greek population with central obesity (assessed by WC) is 23.7% Male gender, presence of insulin resistance and the level of triglycerides, rather than BMI and U/S evidence of fatty liver, are independent predictors of abnormal ALT in patients with central obesity.

Thank you!!!